EUVIMEDEUVIMED entdecken
Crossref

Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management

Jee Suk Chang, Min Hwan Kim, Byung Min Lee, Joohyuk Sohn, Gun Min Kim

International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · 167-175

DOI: 10.1016/j.ijrobp.2026.03.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von Jee Suk Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea; Yo…. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Yonsei University College of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To analyze patterns of progression after first-line systemic therapy in metastatic breast cancer (MBC) patients who did not undergo metastasis-directed therapy (MDT), and to explore whether baseline circulating tumor DNA (ctDNA) copy number aberration burden is associated with progression to widespread metastases. METHODS We reanalyzed a prospective cohort of 207 patients with de novo or recurrent MBC enrolled between 2017 and 2021. Serial imaging studies were retrospectively reviewed to enumerate metastatic lesions and classify progression as involving preexisting lesions (L), new lesions (D), or both (L+D). Lesion burden was categorized as 1-5, 6-10, or >10 lesions. Baseline plasma samples were analyzed using low-pass whole-genome sequencing to quantify genome-wide copy number aberration burden, expressed as the I-score. RESULTS Among 207 patients, baseline lesion counts were 1-5 in 29.5%, 6-10 in 17.9%, and >10 in 52.7%. With a median follow-up of 47.4 months, 5-year overall survival was 75.4% for 1-5 lesions, 65.9% for 6-10 lesions, and 44.9% for >10 lesions, demonstrating a stepwise gradient by baseline lesion count. Patterns of failure were L in 39.3%, D in 27.1%, and L+D in 33.6%, indicating that new lesions accounted for 60.7% of first progression events. Across subsequent therapy lines, progression increasingly manifested as >5 lesions and D-only events. Higher baseline I-score correlated with lesion burden (ρ=0.35, p 10 lesions; HR 3.21, 95% CI 2.01-5.13), along with younger age, triple-negative breast cancer, and higher baseline lesion count. CONCLUSIONS MBC frequently evolves toward widespread dissemination, with new-lesion failures predominating. These patterns provide context for prior MDT trial results and highlight the limitations of lesion count alone. Elevated ctDNA copy-number burden independently predicted widespread progression, supporting further study of ctDNA profiling to identify patients at high risk of rapid dissemination, in whom MDT is unlikely to provide benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating Tumor DNAHumansDisease ProgressionFemaleNeoplasm MetastasisMiddle AgedAgedProspective StudiesAdultRetrospective Studies

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Radiation Oncology, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea; Yonsei Institute for Digital Health, Yonsei University, Seoul, Korea. El…
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea.
  • Department of Radiation Oncology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea. Electronic address: gmkim77@yuhs.ac.

Förderung

  • Yonsei University College of Medicine

Zitieren

APA

Chang, J. S., Kim, M. H., Lee, B. M., Sohn, J., & Kim, G. M. (2026). Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management. International Journal of Radiation Oncology*Biology*Physics, 126(1), 167-175. https://doi.org/10.1016/j.ijrobp.2026.03.012

Vancouver

Chang JS, Kim MH, Lee BM, Sohn J, Kim GM. Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):167-175. doi:10.1016/j.ijrobp.2026.03.012

BibTeX
@article{Chang2026,
  author = {Chang, Jee Suk and Kim, Min Hwan and Lee, Byung Min and Sohn, Joohyuk and Kim, Gun Min},
  title = {Patterns of Progression After First-Line Systemic Therapy in Metastatic Breast Cancer and the Potential of ctDNA to Guide Metastasis-Directed Therapy: Implications for Breast Oligometastases Management},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {126},
  number = {1},
  pages = {167--175},
  doi = {10.1016/j.ijrobp.2026.03.012}
}
Kostenlos starten →